Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

被引：87
作者：
Brock, CS [1 ]
Meikle, SR [1 ]
Price, P [1 ]
机构：
[1] ROYAL PRINCE ALFRED HOSP,PET DEPT,CAMPERDOWN,NSW 2050,AUSTRALIA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1997年 / 24卷 / 06期
关键词：
FDG; oncology; positron emission tomography;
D O I：
10.1007/BF00841411
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Fluoro-deoxyglucose (FDG) is a metabolic marker, which follows the same route into cells as that of glucose, and it can be radiolabelled with fluorine-18, F-18-FDG making it suitable for imaging with positron emission tomography (PET). The fact that rapidly proliferating cells such as tumour cells accumulate F-18-FDG more avidly than those with a normal turnover rate has given rise to its potential in oncology. The rationale and previous published uses of F-18-FDG in oncology are reviewed, together with the various analysis techniques and associated methodological difficulties.
引用
收藏
页码：691 / 705
页数：15
相关论文
共 50 条
  • [1] Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
    C. S. Brock
    S. R. Meikle
    P. Price
    European Journal of Nuclear Medicine, 1997, 24 : 691 - 705
  • [2] PET imaging of musculoskeletal tumours with fluorine-18 α-methyltyrosine:: comparison with fluorine-18 fluorodeoxyglucose PET
    Watanabe, H
    Inoue, T
    Shinozaki, T
    Yanagawa, T
    Ahmed, AR
    Tomiyoshi, K
    Oriuchi, N
    Tokunaga, M
    Aoki, J
    Endo, K
    Takagishi, K
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (10) : 1509 - 1517
  • [3] Fluorine-18 fluorodeoxyglucose uptake in the retractile testis
    Fujii, H
    Yasuda, S
    Ide, M
    Takahashi, W
    Shohtsu, A
    Kubo, A
    CLINICAL NUCLEAR MEDICINE, 1999, 24 (05) : 323 - 325
  • [4] Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
    Rigo, P
    Paulus, P
    Kaschten, BJ
    Hustinx, R
    Bury, T
    Jerusalem, G
    Benoit, T
    FoidartWillems, J
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (12): : 1641 - 1674
  • [5] Fluorine-18 fluorodeoxyglucose uptake in tubovillous adenoma of the colon
    Alibazoglu, H
    Alibazoglu, B
    Hollinger, EF
    Ali, A
    Lamonica, G
    CLINICAL NUCLEAR MEDICINE, 1999, 24 (05) : 357 - 358
  • [6] Variability in the amount of fluorine-18 fluorodeoxyglucose excreted in urine measured from oncology patients during PET/computed tomography imaging
    Soliman, Khaled
    Alenezi, Ahmed
    Alqahtani, Saad
    NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (09) : 992 - 996
  • [7] Sarcopenia and Myositis Revisited Emerging Role of Fluorine-18 Fluorodeoxyglucose PET in Muscle Imaging
    Debs, Patrick
    Al-Zaghal, Abdullah
    Solnes, Lilja B.
    Alavi, Abass
    PET CLINICS, 2023, 18 (01) : 31 - 38
  • [8] Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist
    Cacicedo, Jon
    Navarro, Arturo
    del Hoyo, Olga
    Gomez-Iturriaga, Alfonso
    Along, Filippo
    Medina, Jose A.
    Elicin, Olgun
    Skanjeti, Andrea
    Giammarile, Francesco
    Bilbao, Pedro
    Casquero, Francisco
    de Bari, Berardino
    Dal Pra, Alan
    BRITISH JOURNAL OF RADIOLOGY, 2016, 89 (1067)
  • [9] Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients
    Park, Jong Hoon
    Pahk, Kisoo
    Kim, Sungeun
    Lim, Sang Moo
    Cheon, Gi Jeong
    Park, Yeon Hee
    Lee, Seung-Sook
    Choe, Jae Gol
    ONCOLOGY LETTERS, 2016, 12 (02) : 1620 - 1622
  • [10] Malignant Nature of Cardiac Liposarcoma Revealed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomographic Imaging
    Goto, Toshihiko
    Ohte, Nobuyuki
    Tani, Tomomitsu
    Suda, Hisao
    Kimura, Genjiro
    INTERNAL MEDICINE, 2012, 51 (11) : 1367 - 1370
12345